Lentinan Properties in Anticancer Therapy: A Review on the Last 12-Year Literature
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F17%3A00483487" target="_blank" >RIV/61388971:_____/17:00483487 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.3844/ajisp.2017.50.61" target="_blank" >http://dx.doi.org/10.3844/ajisp.2017.50.61</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3844/ajisp.2017.50.61" target="_blank" >10.3844/ajisp.2017.50.61</a>
Alternative languages
Result language
angličtina
Original language name
Lentinan Properties in Anticancer Therapy: A Review on the Last 12-Year Literature
Original language description
The effects of Beta-glucan in cancer are the most studied biological effects of Beta-glucan. From all available Beta-glucans, the most data are available on lentinan, mostly because it is used in clinical practice for over 20 years. Current review represent a state-of-the-art comprehensive review of knowledge obtained in last twelve years.
Czech name
—
Czech description
—
Classification
Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
10606 - Microbiology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
American journal of immunology
ISSN
1553-619X
e-ISSN
—
Volume of the periodical
13
Issue of the periodical within the volume
1
Country of publishing house
US - UNITED STATES
Number of pages
12
Pages from-to
50-61
UT code for WoS article
—
EID of the result in the Scopus database
2-s2.0-85032071345